Daxor corporation announces novel fluorescent tracer and phasetwo us air force contract award of $750,000 for point-of-care Optical blood volume analyzer
Daxor Corpora9on (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a phase-two contract from the United States Air Force (USAF) to implement a novel fluorescent tracer and op9cal sensing technology into a next-genera9on point-of-care blood volume analyzer. This is the fourth contract award Daxor has received from the Department of Defense (DoD) in the past two years, totaling more than $2 million dollars for the manufacture of advanced blood volume analyzers for military and civilian applications.
“We are pleased to share with the public our innova9ve fluorescing tracer and op9cal blood volume diagnos9c program which has been awarded a $750,000 contract from the USAF. This contract will further enhance the capabili9es for our state-of-the-art technology making precise blood volume measurement both easier and quicker in both combat casualty care and civilian se[ngs,” said Michael Feldschuh, President and CEO of Daxor. “Daxor’s BVA-100 Blood Volume Analysis (BVA) technology transforms the exis9ng standard of care by ensuring resuscita9on and transfusion treatment decisions are based on precise measurement of blood volume for beaer pa9ent survival and outcomes. Our next-genera9on system promises to be even faster, easier, and usable in a broader range of care se[ngs from the baalefield to the outpa9ent clinic to bedside in the ICU.”
“This represents a significant milestone for our technology. The inven9on of a novel fluorescent tracer op9mized for blood volume measurement, for which we have several patents pending, will expand use of our test into more clinical se[ngs for more indica9ons,” said Jonathan Feldschuh, Chief Scien9fic Officer of Daxor. “This tracer will support our next genera9on op9cal analyzer allowing for point-of-care measurement expanding our product offerings to include both nuclear and fluorescing-based tes9ng op9ons. We are excited to accelerate our development under this contract with the DoD.”
The phase-two funding was made possible through the highly compe99ve SBIR program of AFWERX, the USAF team of innovators who encourage and facilitate connec9ons across industry, academia, and the military to create transforma9ve opportuni9es for the development of rapid and affordable commercial and military technologies and solu9ons that meet cri9cal healthcare needs.